Toceranib

SKU: orb1708344

Description

Toceranib phosphate is an orally bioavailable, small molecule tyrosine kinase inhibitor targeting PDGFR, VEGFR, and Kit with high potency. It exhibits antitumor and antiangiogenic activity, making it a useful research tool for studying oncology and angiogenesis in both cellular and animal models.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 356068-94-5
• MW: 396.46
• Purity: 97.62% (May vary between batches)
• Formula: C₂₂H₂₅FN₄O₂
• SMILES: Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1
• Target: VEGFR,c-Kit,PDGFR
• Solubility: DMSO:2.4 mg/mL (6.05 mM)

Bioactivity

• Target IC50:
  FLK1:6 nM (ki)|PDGFRβ:5 nM (ki)
• In Vivo:
  Administration of toceranib significantly decreased the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving toceranib and CYC demonstrated a significant increase in serum concentrations of IFN-γ, which was inversely correlated with Treg numbers after 6 weeks of combination treatment.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CD117, c-Kit, cKit, Inhibitor, Flk-1, inhibit, Kit, PDGFRβ, PDGFR, Platelet-derived growth factor receptor, Vascular endothelial growth factor receptor, VEGFR, SCFR, SU11654, SU-11654, SU 11654, Toceranib, PHA 291639E

Compound Identifiers

PubChem CID

5329106